Intensive Care Articles & Analysis

Yaguo Fight against the Epidemic!! Once again Yaguo have made a donation in order to support the frontline of the epidemic, helping with their innovating products that brings out intensive care and rehabilitation. On March 7th, YAGUO sent to Hubei a new set of respiratory devices, the number goes up to 100 devices worth around 2.2 million RMB, including bionic cough simulator (sputum removal ...

By Beijing Yaguo Technology Co., Ltd.

As the leader in vein visualization technology throughout the world, Christie’s high-quality, made-in-the USA, VeinViewer®Vision2 and VeinViewer® Flex, continue to provide customers with improved clinical outcomes such as increasing 1st stick success, decreasing medically not required PICC lines and enhancing patient satisfaction. We are committed to the continued growth of ...

By Christie Medical Holdings, Inc.

Africa has made considerable progress in improving their health outcomes, despite all the different challenges encountered by the countries. Indicators such as life expectancy and infant mortality improving by the day and showing the efforts of the Governments towards a healthier population. However, there is still a lot to do, since healthcare access in Africa is still constrained by criteria ...

By naseba Lnoppen Co. Ltd - part of the naseba group

The widespread assumption that pandemic influenza is an exceptionally deadly form of seasonal, or nonpandemic, flu is hard to support, according to a new study in the May issue of the American Journal of Public Health. The study challenges common beliefs about the flu--in particular the Centers for Disease Control and Prevention (CDC) claim that 'the hallmark of pandemic influenza is excess ...

By MIT - Massachusetts Institute of Technology

For little lungs everywhere, the families that love them, and the neonatologists who care for them, there’s news coming out of ONY Biotech, a family-focused neonatology pharmaceutical company. Today, ONY Biotech announced the results of a clinical trial on its aerosolized surfactant for newborns with respiratory distress syndrome (RDS), a disorder caused by lack of surfactant that can ...

By ONY Biotech

Respiratory Motion INC. (RMI) today announced the appointment of Laura Piccinini as Chief Executive Officer effective immediately. Piccinini served on the RMI Board of Directors since the beginning of 2020. She succeeds Dr. Jenny Freeman, CEO since 2012. Laura is an executive with an outstanding career in the medical device industry including successful leadership assignments across multiple ...

By Respiratory Motion, Inc.

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...

By Palisade Bio

MARTINEZ, Calif. – ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). Per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval of Seraph 100 ...

By ExThera Medical Corporation

Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19. The cSOFA score (Covid Sequential Organ Failure Assessment) measures the likelihood of clinical deterioration in Covid-19 patients, enabling triage and assignment to the general ward or intensive care units (ICU) upon admission and during the patients’ hospital stay. ...

By Abionic SA

CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world's first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, using solely ultrasound ...

By CoapTech

Researchers in London, Ont., are the first in the world to use a new device for feeding tube insertion that can improve patient safety and reduce the cost of health-care services. A team from Lawson Health Research Institute has partnered with CoapTech LLC, a medical device company, to study the use of the PUMA-G System. In October of last year, the medical and research teams were the first in ...

By CoapTech

Inspiration Healthcare Group plc is pleased to announce the opening of its new corporate head office in the Manor Royal Business District, Crawley, UK. The newly redeveloped 4,500 ft2 office in the Satellite Business Village was officially opened on Friday 3rd March 2017 by Henry Smith MP who unveiled a commemorative plaque and joined guests, the Inspiration Healthcare Group plc Board of ...

By Inspiration Healthcare Group plc

N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. N8 Medical is encouraged by preliminary study data and believes that the CeraShield™ ETT will demonstrate safety and a significant ...

By N8 Medical, LLC

Hyperfine, Inc. (Nasdaq:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, is proud to announce that Queen’s University and Kingston Health Sciences Centre are deploying a Swoop system as part of their health services benefitting six communities located in the James Bay and Hudson Bay Area. Until now, patients needing routine or ...

By Hyperfine

Fab’entech, a Lyon-based biopharmaceutical company specialised in immunotherapies for emergency situations, is today announcing the launch of a programme to develop an immunotherapy treatment against COVID-19. The treatment will be indicated in severely ill patients requiring respiratory assistance. The clinical trials are expected to begin in humans in 2021. In order to meet the new ...

By Fab’entech

Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful closing of a CHF20 million Series C financing. The round was led by Pierangelo Bottinelli, Chairman of Symphony International Holdings Limited, and included Philippe Glatz (Chairman of two private hospitals), Peter Brabeck-Letmathe (former CEO and Chairman of Nestlé), ...

By Abionic SA

The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic and diverse representation in STEM, today announced an initiative with the Ministry of Health and Population (MoHP) in Nepal to control the spread of SARS-CoV-2 throughout the country. With contributions from Sherlock Biosciences, Open Philanthropy, Integrated DNA Technologies ...

By Sherlock Biosciences, Inc.

BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Propofusor product containing 1% propofol in a single-use dispensing system. Uses of the Propofusor include the induction and maintenance of general anesthesia, sedation of mechanically ventilated ...

By BioQ Pharma

Products from Intus Biosciences demonstrated high-resolution tracking of specific bacterial strains in a recent microbiome study, the results of which are being applied to better understand how pathogens and commensals become established in premature infants in neonatal intensive care units (NICU), with the goal of improving outcomes for premature infants. Intus Biosciences is a microbiome ...

By Intus Biosciences, LLC

In November of last year, a new study was published in the American Journal of Infection Control (AJIC). It indicated the common presence of Acinetobacter baumannii (MDR-AB), a dangerous multi-drug resistant bacterium, in numerous patient rooms in healthcare settings. Researchers found that MDR-AB was present in the indoor environment of 48% of the rooms of patients infected or colonized by the ...

By Cochrane & Associates, LLC